Clinical Trials

A Phase I Open Label First in Human Dose Escalation of the immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination with Dexamethasone in Participants with Relapsed Refractory Multiple Myeloma


Study ID
MS201814-0010

NCT Number
NCT04075721 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0242

Principle Investigator
Dr. Siegel, David

Phase
I

Sponsor
EMD Serono Research & Development Institute, Inc.


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now